INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
Omai Gold Mines Corp. (TSXV: OMG) (OTCQB: OMGGF) ("Omai Gold" or the "Company") is pleased to announce assay results from the next phase of drilling at its 100% owned Omai Gold Project in Guyana, ...
A study launched at the ADEA Triennale in Ghana analysed data from early grade reading assessments (EGRAs ... using the accompanying how to guide to help tailor implementation.” ...
Phase 2 will also update capital and operating costs to reflect inflation and other changes since the Feasibility Study. Phase 1 was overseen by Highland ... Studies indicate that approximately 7.9 ...
Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) ...
Gilead Sciences, Inc. and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition ...
Genmab A/S today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin's ...
Omai Gold Mines Corp. (TSXV: OMG) (OTCQB: OMGGF) ("Omai Gold" or the "Company") is pleased to announce assay results from the next phase of drilling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback